[Skip to Content]
[Skip to Content Landing]
Views 3,075
Citations 0
September 2016

Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742.

Author Affiliations
  • 1Editor in Chief, JAMA
  • 2Editor, JAMA Internal Medicine
  • 3Department of Medicine, University of California, San Francisco
JAMA Intern Med. 2016;176(9):1256. doi:10.1001/jamainternmed.2016.3177

The following article, Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005;165(15):1737-1742,1 has been retracted due to acknowledgment of scientific misconduct resulting in concerns about data integrity and inappropriate assignment of authorship.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    “Notice of Retraction”- The patients and society.
    Dr.Rajiv Kumar, Dr.Jagjit Singh. | Faculty, Deptt. of Pharmacology. Government Medical College & Hospital, Chandigarh, 160030, India.
    We are sincerely thankful to the Editor in Chief, JAMA and the Editor, JAMA Internal Medicine for giving “Notice of Retraction” to Sato Y, et al., due to acknowledgment of scientific misconduct.
    This research paper (now retracted research paper) has an Altmetric score of 6, which is a high-level measure of the quality and quantity of online attention, 1blog post & 33 citations so far.
    But this raises many questions in the scientific community because the articles published in journals of JAMA network are accepted by the academics and researchers wholeheartedly all over
    the world.
    This research paper published in Aug, 2005 and “Notice of Retraction” issued this year (Published Online: June 3, 2016. doi:10.1001/jamainternmed. 2016.3177), within this period the scientific community well utilized the facts of this article for research purpose, for meta-analysis, for research projects, and to prepare guidelines by the scientific bodies all over the world.
    The time-money and manpower has been affected, but the pharmaceutical companies got benefits most.
    The patients and society is affected largely more than others and it looks that cheated, ultimately affect faith and trust to the journal and its published articles.

    Regards ,
    Dr Rajiv Kumar, Dr Jagjit Singh. Faculty, Deptt. of Pharmacology. Government Medical College & Hospital, Chandigarh, 160030, India.